![]() |
市場調查報告書
商品編碼
1663314
出血控制系統 - 市場洞察、競爭格局、2032年市場預測Hemorrhage Control System - Market Insights, Competitive Landscape, and Market Forecast - 2032 |
預測期內,即2025-2032年,全球出血控制系統市場規模預計將以 4.87%的年複合成長率成長。出血控制系統的需求主要源自於創傷和損傷發生率的上升。此外,全球外科手術數量的增加和慢性病盛行率的上升是2025-2032年預測期內推動市場成長的主要因素。
出血控制系統的市場動態
由於創傷和損傷發生率的上升以及慢性病的盛行率不斷上升,對出血控制系統的需求呈現出顯著成長。根據最近發表在『Traumatic brain injury: Epidemiology, classification, and pathophysiology』上的一項研究,創傷性腦損傷(TBI)是全球主要的健康問題,每年影響約 2700萬至 6900萬人。 TBI 常導致各種形式的顱內出血,包括硬膜外、硬腦膜下和蜘蛛膜下腔出血,需要立即介入以防止進一步的腦損傷和死亡。顱內出血會導致顱內壓升高,加重腦損傷,因此及時採取止血措施十分必要。由於創傷相關的損傷仍然是全球發病率和死亡率的重要原因,預計在2025-2032年預測期內對有效出血控制系統的需求將激增。
除創傷病例外,因慢性病盛行率不斷上升而導致的手術數量增加也是出血控制系統市場的主要動力。根據British Heart Foundation(2024)的資料,全球約有 6.2億人患有心臟和循環系統疾病,大約每 13 人就有 1 人。這些患者通常接受抗凝血和抗血小板治療以降低凝血風險,因此更容易在創傷、手術或自發性出血期間出現過度出血。 GLOBOCAN(2022)估計,2022年全球將有約 1,990萬人患有癌症,其中許多人將接受需要有效止血的侵入性手術。慢性病流行、抗凝血劑的廣泛使用以及手術量的增加,推動了對急性和外科環境中可靠的出血控制解決方案的需求。
儘管市場成長前景看好,但某些挑戰可能會抑制其擴張。先進的止血產品的高成本和與這些設備相關的潛在副作用仍然是主要阻礙因素。透過具有成本效益的創新和改進的安全性來解決這些障礙對於充分利用日益成長的需求非常重要。
整體而言,由於創傷、慢性病和外科手術的盛行率上升,出血控制系統市場預計將在2025-2032年預測期內實現正成長。
北美預計主導整個出血控制系統市場
由於慢性病患病率上升、外科手術增多、創傷和損傷發生率高以及醫療保健基礎設施先進等多種因素,預計北美將在2024年佔據全球出血控制系統市場的最大佔有率。該地區良好的產品發布和監管審批環境將進一步促進市場成長。
根據2023年 PubMed Central 發表的一項研究,美國每年約有 4000萬人次因創傷而到急診室(ED)就診。創傷仍然是 46 歲以下人口死亡的主要原因,佔該年齡層所有死亡人數的近一半。交通事故是造成創傷的主要原因,經常會導致嚴重出血,需要立即進行醫療干預。這導致緊急醫療環境中對止血帶、壓力繃帶和止血劑等止血設備的需求增加。
本報告分析了全球出血控制系統市場,並提供了有關市場規模和預測、過去三年的產品和技術發展、市場主要參與者以及可用機會的資訊。
Hemorrhage Control System Market by Product (Hemorrhage Control Devices, Hemostatic Agents, and Others), Application (Cardiovascular Surgery, General Surgery, Orthopedic Surgery, and Others), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising incidence of trauma and injuries and increasing surgical procedures across the globe.
The hemorrhage control system market is estimated to grow at a CAGR of 4.87% during the forecast period from 2025 to 2032. The demand for hemorrhage control systems is primarily driven by the rising incidence of trauma and injuries. Additionally, the growing number of surgical procedures worldwide and the increasing prevalence of chronic diseases are key factors contributing to the market's growth during the forecast period of 2025 to 2032.
HEMORRHAGE CONTROL SYSTEM MARKET DYNAMICS:
The demand for hemorrhage control systems is witnessing significant growth, driven by the rising incidence of trauma, and injuries, and the increasing prevalence of chronic diseases. According to a recent study published in the journal Traumatic Brain Injury: Epidemiology, Classification, and Pathophysiology, traumatic brain injury (TBI) is a major global health concern, affecting an estimated 27 to 69 million people annually. TBI frequently results in various forms of intracranial hemorrhage, including epidural, subdural, and subarachnoid bleeding, which require immediate intervention to prevent further brain damage or death. Intracranial bleeding elevates intracranial pressure, exacerbating brain injury and underscoring the critical need for timely hemorrhage control solutions. As trauma-related injuries remain a significant contributor to global morbidity and mortality, the demand for effective hemorrhage control systems is expected to surge during the forecast period from 2025 to 2032.
Beyond trauma cases, the growing number of surgical procedures driven by the increasing prevalence of chronic diseases is another key factor propelling the hemorrhage control system market. According to the British Heart Foundation (2024), approximately 620 million people worldwide live with heart and circulatory diseases, equating to roughly 1 in 13 individuals. These patients, often on anticoagulant or antiplatelet therapies to mitigate clotting risks, face a heightened likelihood of excessive bleeding during trauma, surgery, or spontaneous hemorrhages. Similarly, cancer prevalence further drives surgical interventions; GLOBOCAN (2022) estimated that approximately 19.9 million people globally were living with cancer in 2022, many of whom undergo invasive procedures requiring efficient hemorrhage management. The intersection of chronic disease prevalence, widespread use of blood-thinning medications, and increasing surgical volumes underscores the growing need for reliable hemorrhage control solutions in both emergency and operative settings.
Despite the market's promising growth prospects, certain challenges may restrain expansion. The high cost of advanced hemorrhage control products and potential side effects associated with these devices remain notable constraints. Addressing these barriers through cost-effective innovations and improved safety profiles will be essential to fully capitalize on the increasing demand.
Overall, fueled by the rising prevalence of trauma, chronic diseases, and surgical interventions, the hemorrhage control system market is poised for positive growth during the forecast period of 2025 to 2032.
HEMORRHAGE CONTROL SYSTEM MARKET SEGMENT ANALYSIS:
Hemorrhage Control System Market by Product (Hemorrhage Control Devices, Hemostatic Agents, and Others), Application (Cardiovascular Surgery, General Surgery, Orthopedic Surgery, and Others), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the hemorrhage control system market, the hemorrhage control devices category is projected to secure a significant revenue share in 2024. This growth is attributed to the wide range of advantages and critical applications these devices offer in emergency and surgical settings. Designed to rapidly stop or minimize blood loss, these devices play a vital role in preventing shock and fatal complications resulting from hemorrhage.
Devices such as tourniquets and hemostatic dressings can be applied within seconds, significantly improving survival rates in trauma cases by controlling bleeding during the critical "golden hour" following an injury. Early intervention with these devices stabilizes patients until professional medical care becomes available, increasing the likelihood of positive outcomes. Furthermore, advancements in technology have led to the development of specialized devices like junctional tourniquets, which effectively manage bleeding in challenging anatomical regions such as the groin and armpit areas where traditional methods may prove inadequate.
The increasing adoption of these devices in both civilian and military settings, coupled with their ease of use and effectiveness in pre-hospital environments, is further fueling demand. Additionally, growing awareness of the importance of immediate hemorrhage control and the implementation of emergency response protocols across various sectors are driving market expansion.
Therefore, owing to these factors, the hemorrhage control system devices category is expected to register significant growth, thereby propelling the overall hemorrhage control system market during the forecast period.
NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL HEMORRHAGE CONTROL SYSTEM MARKET:
North America is projected to account for the largest share of the global hemorrhage control system market in 2024, driven by several key factors, including the rising prevalence of chronic diseases, an increasing number of surgical procedures, a high incidence of trauma and injuries, and the presence of advanced healthcare infrastructure. The region's favorable environment for product launches and regulatory approvals further contributes to market growth.
According to a 2023 study published in PubMed Central, traumatic injuries account for approximately 40 million emergency department (ED) visits annually in the United States. Trauma remains the leading cause of mortality among individuals under 46 years of age, responsible for nearly half of all fatalities in this age group. Road traffic accidents, a major cause of trauma, frequently lead to severe bleeding that necessitates immediate medical intervention. This has heightened the demand for hemorrhage control devices such as tourniquets, pressure bandages, and hemostatic agents in emergency care settings.
The rising burden of chronic diseases in North America further drives the need for surgical interventions requiring effective hemorrhage management. Patients with cardiovascular conditions, cancer, or those on anticoagulant therapies are at increased risk of bleeding complications during surgeries or in emergencies, amplifying the demand for reliable hemorrhage control solutions.
Additionally, product innovations and regulatory approvals in the region play a significant role in market expansion. For example, in November 2023, Ethicon, a Johnson & Johnson MedTech company, received approval for ETHIZIA(TM), an adjunctive hemostat solution clinically proven to achieve sustained hemostasis in difficult-to-control bleeding situations. Such advancements highlight the region's robust innovation ecosystem and commitment to improving patient outcomes.
Therefore, the combination of a high trauma burden, increasing surgical volumes, a supportive regulatory environment, and continuous product innovation is expected to drive substantial growth in the hemorrhage control system market in North America during the forecast period of 2025 to 2032.
HEMORRHAGE CONTROL SYSTEM MARKET KEY PLAYERS:
Some of the key market players operating in the hemorrhage control system market include Medtronic, MED Alliance Group, Inc., Organon, EndoClot Plus, Inc., Aero Healthcare AU Pty Ltd., Stryker, Safeguard, Zimmer Biomet, Sam Medical, RevMedx, BD, Baxter, Johnson & Johnson, Hemostasis, LLC., Pfizer, Starch Medical, Inc., Teleflex Incorporated, Arch Therapeutics, Inc., Dilon Technologies, Medtrade Products Ltd., and others.
RECENT DEVELOPMENTAL ACTIVITIES IN THE HEMORRHAGE CONTROL SYSTEM MARKET:
KEY TAKEAWAYS FROM THE HEMORRHAGE CONTROL SYSTEM MARKET REPORT STUDY
TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS HEMORRHAGE CONTROL SYSTEM MARKET REPORT STUDY
FREQUENTLY ASKED QUESTIONS FOR THE HEMORRHAGE CONTROL SYSTEM MARKET: